Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. - Wikidata - awgldk - TriplyDB

Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey.

Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey.

http://www.wikidata.org/entity/Q37001036

about

Fatigue Management in Multiple Sclerosis Assessing Four Quality Indicators for Multiple Sclerosis Management Through Patient-Reported Data Children and adolescents adjustment to parental multiple sclerosis: a systematic review Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort.Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication International Differences in Multiple Sclerosis Health Outcomes and Associated Factors in a Cross-sectional Survey Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study.Randomized controlled trial of a teleconference fatigue management plus physical activity intervention in adults with multiple sclerosis: rationale and research protocol.Quality of life in multiple sclerosis.Lifestyle factors, demographics and medications associated with depression risk in an international sample of people with multiple sclerosis.Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis Clinically significant fatigue: prevalence and associated factors in an international sample of adults with multiple sclerosis recruited via the internet Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis.Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability Comparison of the psychometric properties of two fatigue scales in multiple sclerosis MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial.Tracking daily fatigue fluctuations in multiple sclerosis: ecological momentary assessment provides unique insights.Adherence to monthly online self-assessments for short-term monitoring: a 1-year study in relapsing-remitting multiple sclerosis patients after start of disease modifying treatment.Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort.Methodology of an International Study of People with Multiple Sclerosis Recruited through Web 2.0 Platforms: Demographics, Lifestyle, and Disease Characteristics.Predictors of Fatigue Impact in Persons With Long-Standing Multiple Sclerosis Association of fish consumption and Ω 3 supplementation with quality of life, disability and disease activity in an international cohort of people with multiple sclerosis.Prevalence of fatigue in patients with multiple sclerosis and its effect on the quality of life.Developing a wellness program for people with multiple sclerosis: description and initial results.Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab: The ENER-G Study.Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.Physical activity in subjects with multiple sclerosis with focus on gender differences: a survey.Quality of life in multiple sclerosis: effects of current treatment options.Multiple sclerosis-associated fatigue.Fatigue in healthy and diseased individuals.Fostering adherence to injectable disease-modifying therapies in multiple sclerosis.Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.Understanding fatigue in paediatric multiple sclerosis: a systematic review of clinical and psychosocial factors.Translating Fatigue to Human Performance.Symptomatic treatment in multiple sclerosis-interim analysis of a nationwide registry.Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis.Quality of life among people with multiple sclerosis: Replication of a three-factor prediction model.

P2860

Q26752946-DABA7042-AFFD-4D84-8185-44202A875DA3 Q31123075-549792C0-AF4C-4F91-B9C1-F3A4B13D3727 Q33694029-A5550A29-CE94-4F2A-B495-6DAAE80D2770 Q33712460-21B7EDB1-D1C8-42B9-9B5B-FBA839AE3BB4 Q33735739-72773419-E9FE-41E1-8CC6-92F65CE638BB Q33742328-C487D929-7DF7-43D2-A222-FB07BD9FC159 Q34021881-8846EBEC-448B-41F4-B00C-7412D74D52CD Q34393224-4F068785-F956-49FE-AFCB-965E1A1233DA Q34448537-58BE200C-564A-4E17-B625-58CAC646EAA6 Q34481312-CDC126BB-1C01-4AAA-9DFC-F5909E50A205 Q34677081-3A2DFEB0-1B67-4DD3-B8F5-DB241216061E Q34687024-8375BCCE-AE41-4839-AB97-15DEE605FE8B Q35097889-AFFCC12F-5F77-4EC5-9DAB-EA9BDE08D5B7 Q35103997-8FDF9801-C808-4AF4-8A13-C95115BD23C3 Q35743570-30EA9BB9-D60C-41B2-8841-66A8CBECCF1F Q35843867-356E5E2C-523D-4E1F-9E16-41D25232005B Q35866381-8781ADFD-ED8B-4AB4-B280-E3778A92FC28 Q36174605-FA8E516D-B5D4-4293-A68F-658A7A185D03 Q36293816-2918E936-0C46-4D7E-A568-CBB83070B87A Q36303789-8B043DF9-C59F-4F4B-9354-9B1DD0F86B9A Q36761902-00B13A65-917D-4D8F-AAAD-80E2794B0373 Q36777636-8ED8FE36-E9AC-4647-A5C8-0BE8964061A2 Q36830898-0B165DD7-76F3-41C8-8C81-198FE71FFFCA Q36860594-47041FC0-9636-4AB7-A6A7-CA64D0C0420B Q37290620-CC43B713-B163-4376-9B36-C2E7E4D662DF Q37290749-3F947BD0-F9B2-41E7-9796-1013524A80AB Q37442117-62A43569-E200-4C32-8E0C-F9D5FC3FBC17 Q37442396-99556DD1-125C-4052-90A5-679B6048CE65 Q37519608-599EA552-1992-41BA-8D12-6FF8814A3940 Q37684368-AEDFDE89-2BBA-4508-B056-1619FB5CA20D Q37710122-7F4C7F70-740F-48BB-AD2A-5E98A8613E3C Q37785555-6934623C-3AAE-4130-875D-189FC2D4EFE4 Q38124676-01862140-A659-45AD-8F85-D427AE850583 Q38238548-8DE62C20-FB4D-401D-B445-6DEC808C6D00 Q38267110-18042F8B-4122-4422-8F6C-9C6B0EF7F5DB Q38632953-A8132252-34CF-45AF-B4B2-2E93E16A2C04 Q38789024-B4956944-DF9E-4F9A-9928-F0EE05A0B687 Q38855448-C9523724-6F34-4E04-B858-58FC1F42C948 Q39672574-D4A206D1-FB2B-4659-B768-439D49E1DBC4 Q40240777-95BDDEAE-4F82-4FBE-8D8F-57C52D4ACCAE

P2860

Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey.

http://www.wikidata.org/entity/Q37001036

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Fatigue characteristics in mul ...... le Sclerosis (NARCOMS) survey.

@en

Fatigue characteristics in mul ...... ommittee on Multiple Sclerosis

@nl

type

label

Fatigue characteristics in mul ...... le Sclerosis (NARCOMS) survey.

@en

Fatigue characteristics in mul ...... ommittee on Multiple Sclerosis

@nl

prefLabel

Fatigue characteristics in mul ...... le Sclerosis (NARCOMS) survey.

@en

Fatigue characteristics in mul ...... ommittee on Multiple Sclerosis

@nl

P1433

Q37001036-BA128E68-D921-4976-A8A1-08211C13A38A

P1476

Q37001036-DDADDC79-BECD-47C5-8177-026A9D017DE0

P2093

Q37001036-242F29AE-0675-4ED5-895E-CF03B2EE263C

Q37001036-76AFA76D-88D2-452B-AB2F-F3FBD263138A

Q37001036-9A69F72D-7F88-45D4-AA54-083DE34764F0

Q37001036-B872FBC2-011C-4A40-8F71-D0E9E18479F8

P2860

Q37001036-0457E6AF-2FDF-48B5-9D98-6CAB02551D10

Q37001036-128BC3DF-7FED-4C89-9812-CBD046C0F9BA

Q37001036-16C3BC2E-8C50-439A-B541-DB66C6F72C87

Q37001036-223724ED-B1CE-4405-AFF0-CA073568A2E9

Q37001036-22B595CD-0D39-4A44-93B5-70B36D888FB0

Q37001036-23E48401-651A-4388-B5E0-885C70F8E25B

Q37001036-2E0678E5-FD4F-4D82-83EA-A3B042CA019B

Q37001036-3301D13B-9F03-49D6-9987-8544C3CBC559

Q37001036-3AF089C8-6A2A-4622-9581-D9ADD71C16BE

Q37001036-59B0AD0C-F449-4A30-870B-AE6A45E05BFA

P2888

Q37001036-FB7176F2-27B0-4697-A924-71C0C9C39A67

P304

Q37001036-3E002E33-6E21-42F2-9564-A2FB384912CD

P31

Q37001036-073459E5-E064-432D-A675-6C267F414A9D

P356

Q37001036-96B08406-3BAF-4C38-8B43-3803F46652AE

P478

Q37001036-C97BDCAD-9A0F-4AC6-9ACB-2E205424EFA8

P577

Q37001036-08FB2E66-2C98-49E8-9A4E-3FCF59D2482F

P5875

Q37001036-6681146D-89A6-46D3-A160-12E4BA206477

P6179

Q37001036-252D5E84-0573-42C6-A0C7-6F2A12587D10

P698

Q37001036-D596B6E4-9104-4FD0-870C-F55C79331D85

P921

Q37001036-1DD1A1A9-CD77-44D0-AF2E-82D3330DB540

P932

Q37001036-ABACD733-29E9-417D-8B96-54B0FC914240

P356

1477-7525-6-100

P1433

Health and Quality of Life Outcomes

P1476

Fatigue characteristics in mul ...... le Sclerosis (NARCOMS) survey.

@en

P2093

MerriKay Oleen-Burkey

http://www.w3.org/2001/XMLSchema#string

North American Research Committee on Multiple Sclerosis

http://www.w3.org/2001/XMLSchema#string

Olympia Hadjimichael

http://www.w3.org/2001/XMLSchema#string

Timothy Vollmer

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Multiple sclerosis: side effects of interferon beta therapy and their management

Fatigue associated with multiple sclerosis: diagnosis, impact and management

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.

Physiopathology and treatment of fatigue in multiple sclerosis.

Fatigue in multiple sclerosis: definition, pathophysiology and treatment.

The effect of immunomodulatory treatment on multiple sclerosis fatigue.

Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

Origin of fatigue in multiple sclerosis: review of the literature.

P2888

1477-7525-6-100

P304

100

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1477-7525-6-100

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23478844

http://www.w3.org/2001/XMLSchema#string

P6179

1009699008

http://www.w3.org/2001/XMLSchema#string

P698

19014588

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

2596785

http://www.w3.org/2001/XMLSchema#string